Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma
| Status: | Archived |
|---|---|
| Conditions: | Skin Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | October 2010 |
| End Date: | August 2012 |
A Phase 2, Open Label, Non-Randomized Study to Evaluate the Safety, Tolerability, Immune Response and Clinical Response of Multiple Doses of MKC1106-MT in Subjects With Advanced Melanoma
The clinical trial is evaluating a multi-component active immunotherapy designed to
stimulate an immune reaction to specific tumor associated antigens which are highly
expressed on melanoma
The multi-component active immunotherapy, MKC1106-MT, consists of 1 plasmid dose and 2
peptides doses designed to stimulate an immune reaction to two tumor associated antigens
(Melan-A and tyrosinase). The plasmid component will be administered on Days 1, 4, 15 and
18 of each treatment cycle followed by administration of peptides on Days 29 and 32 of the
treatment cycle. All components will be administered separately into non-diseased
superficial inguinal lymph nodes under ultrasound guidance
We found this trial at
4
sites
501 SE Osceola St # 100
Stuart, Florida 34994
Stuart, Florida 34994
Click here to add this to my saved trials
Click here to add this to my saved trials
UCLA Medical Center Founded in 1955, UCLA Medical Center became Ronald Reagan UCLA Medical Center...
Click here to add this to my saved trials
Click here to add this to my saved trials